13 minute read
May 1, 2024
Schrödinger’s MALT1 Inhibitor Showcases the Potential of its Computational Platform and Becomes Its First In-House Clinical Compound
SGR-1505
oral, allosteric MALT1 inhibitor Ph. I compound for mature B cell neoplasm computer-aided drug design from literature starting point ACS Spring 2024 meeting presentation Schrödinger, New York, NY